ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Wearable device with AI could allow for at-home breast cancer screenings: ‘Accessible and personalized'

Researchers at MIT are developing a wearable ultrasound scanner to enable women to screen for breast cancer at home. Dr. Harvey Castro weighed in on the benefits and risks.

To provide women at a high risk of breast cancer with more frequent screenings between mammograms, researchers at the Massachusetts Institute of Technology (MIT) are developing a wearable ultrasound scanner designed to be attached to a bra.

The goal is to help women detect breast cancer tumors in the early stages and maximize the survival rate, according to a press release on MIT’s website.

The researchers’ aim was to design a wearable "miniaturized ultrasound device" that allows for "consistent placement and orientation" to take images of breast tissue, according to lead study author Canan Dagdeviren, PhD, associate professor at MIT.

WHAT IS ARTIFICIAL INTELLIGENCE (AI)?

The device attaches to the bra like a patch, with a "honeycomb" pattern that has open spaces for the tracker to move through for an optimal field of view, Dagdeviren told Fox News Digital. 

"The ultrasound generates a wave that penetrates the targeted breast tissue," he said. 

"When the ultrasound wave sees an obstacle like a tumor, it reflects [that] — and the ultrasound device captures this reflected wave and generates a black-and-white ultrasound image."

He added, "From this image, you can find the coordination and shape of any anomaly in the soft breast tissue."

AI TECH AIMS TO DETECT BREAST CANCER BY MIMICKING RADIOLOGISTS’ EYE MOVEMENTS: 'A CRITICAL FRIEND'

In a study, a woman with a history of breast cysts wore the bra and patch, and the researchers scanned the breast at six different locations according to the patch design. 

The technology recorded the images of the breast tissue, which displayed cysts as small as 0.3 centimeters in diameter the approximate size of tumors at early stages of the disease. 

The device is designed as a complement to traditional screenings by medical professionals rather than a replacement, Dagdeviren said.

"For personal health care and monitoring at home, this device can be considered as a replacement [for] the conventional handheld probe or ABUS system at the early stage of breast tumor imaging," he said. 

"For breast tumor diagnosis, this device can be a strong complement to existing screening methods, making long-term breast imaging efficient and convenient."

In the future, researchers plan to use artificial intelligence to analyze the ultrasound images and make diagnostic recommendations.

"The AI integration has the potential to enhance diagnostic accuracy through data analysis, and also holds potential for early detection and personalized care pathways for other diseases," Dr. Harvey Castro, a Dallas, Texas-based board-certified emergency medicine physician and national speaker on AI in health care, told Fox News Digital.

Castro was not involved in the research but reviewed the details of the device.

It could be three or four years before the device is available to consumers, Dagdeviren said. 

"The critical step is the portable system and wireless communication to the hospital," he told Fox News Digital.

NEW AI ULTRASOUND TECH IS FIRST TO LAND FDA APPROVAL TO ENHANCE PRENATAL CARE: ‘BETTER HEALTH OUTCOMES’

The company will also need to complete intensive human trials and gain FDA approval — something that Dagdeviren expects to cost around $40 million.

Dagdeviren said he does not foresee any safety risks associated with the device, as it does not use radiation.

Also, the wearable ultrasound patch can be used over and over, the release on MIT website's noted. It could also help diagnose cancer in people who don’t have regular access to screening.

The device requires a long, flexible cable to connect the image processing system, the study's lead author noted. 

Additionally, the system that collects all of the data is currently large and stationary.

"We are currently working on a portable system, which we hope to publish in a few months," Dagdeviren said.

The imaging resolution is "sufficient, but not superior," he noted, and the researchers are working on various image processing methods. 

"In our next paper and patent, all of these limitations will be eliminated in around six months," Dagdeviren said.

"The development of this wearable device for breast cancer detection represents a significant advancement in health care technology," Castro told Fox News Digital. 

"Its potential to save lives and extend its promise to other diseases is immense."

Castro added, "However, careful consideration of its implementation, including rigorous testing, alignment with existing medical protocols, and ethical considerations, will be essential to its success."

To maximize the potential of this technology, he emphasized the need to "strike a balance between innovation and responsible medical practice."

There is also the need to ensure the privacy and security of personal health data and to consider "potential disparities in access," especially if the device becomes a commercial product, Castro noted.

AI BABIES: NEW TECHNOLOGY IS HELPING FERTILITY DOCS CHOOSE THE BEST EMBRYOS FOR IVF

Depending on the user’s skill level, there could also be a risk of inconsistencies and inaccuracies, he pointed out.

"It embodies the convergence of technology and health care, reflecting a future where medical care is more accessible and personalized," Castro said. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

"However, it cannot replace traditional mammograms and other preventive care from a breast cancer expert."

Aside from skin cancers, breast cancer is the most common cancer in U.S. women, representing one in three of all female cancer diagnoses each year, according to the American Cancer Society.

When breast cancer is caught early, the five-year survival rate is 99%. If it is detected in advanced stages, the survival rate is only 25%.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.